Plain-English translation of NCT07165132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing , a new radioactive medication designed to find and attack cancer cells that have a specific protein called somatostatin receptors. The study is designed for people with neuroendocrine tumors (slow-growing cancers that can start in the digestive system, pancreas, or other organs) or certain other solid tumors. Researchers will gradually increase the dose to find the safest and most effective amount, and they'll watch closely to understand how well the medication works and what side effects occur.
Neuroendocrine tumors and some other cancers are difficult to treat, especially when they've spread or can't be surgically removed. This new radioactive treatment is designed to work better by targeting cancer cells more precisely, which could help patients live longer and with fewer severe side effects than current options.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication at the study clinic, with the dose starting low and gradually increasing as researchers monitor your safety. Throughout the study, you'll have regular blood tests, imaging scans, and visits with the study doctors to check how you're responding and whether you're having side effects. The study involves about 104 people total, and your participation will help determine the best dose and treatment schedule for future patients.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States